We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+1.76%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.47B
AUM Growth
+$179M
Cap. Flow
+$251M
Cap. Flow %
17.06%
Top 10 Hldgs %
60.67%
Holding
38
New
8
Increased
19
Reduced
3
Closed
7

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$63.6M
2
ARGX icon
argenx
ARGX
+$58.3M
3
TGTX icon
TG Therapeutics
TGTX
+$50.5M
4
OLMA icon
Olema Pharmaceuticals
OLMA
+$41.5M
5
BCYC
Bicycle Therapeutics
BCYC
+$37.9M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$61.5M
2
ONC
BeOne Medicines Ltd
ONC
+$38.5M
3
INCY icon
Incyte
INCY
+$29.6M
4
VIR icon
Vir Biotechnology
VIR
+$24.9M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$19.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LEGN icon
1
Legend Biotech
LEGN
$4.3B
$136M 9.23%
2,025,480
+219,763
+12% +$15.3M
ARGX icon
2
argenx
ARGX
$57.4B
$129M 8.72%
261,443
+119,184
+84% +$58.3M
ACLX
3
DELISTED
Arcellx
ACLX
$106M 7.19%
2,953,122
+606,122
+26% +$20.9M
OLMA icon
4
Olema Pharmaceuticals
OLMA
$1.02B
$96.4M 6.54%
7,803,600
+4,072,554
+109% +$41.5M
NUVL
5
DELISTED
Nuvalent
NUVL
$75.3M 5.11%
1,638,147
+517,682
+46% +$23M
BCYC
6
Bicycle Therapeutics
BCYC
$270M
$73.2M 4.97%
3,642,307
+1,656,877
+83% +$37.9M
MRTX
7
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$72.7M 4.93%
1,668,116
+224,354
+16% +$8.01M
IMCR icon
8
Immunocore
IMCR
$1.78B
$71.9M 4.88%
1,384,686
+114,562
+9% +$6.78M
UTHR icon
9
United Therapeutics
UTHR
$26.3B
$69.4M 4.71%
307,314
+68,926
+29% +$15.9M
CRNX icon
10
Crinetics Pharmaceuticals
CRNX
$8.86B
$64.8M 4.4%
2,178,737
+783,735
+56% +$16.2M
IRON icon
11
Disc Medicine
IRON
$2.83B
$59.8M 4.06%
+1,272,279
New +$63.6M
VRDN icon
12
Viridian Therapeutics
VRDN
$2.13B
$56.5M 3.83%
3,681,747
+1,266,491
+52% +$24.2M
CERE
13
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$55.3M 3.75%
2,532,972
+664,026
+36% +$16.6M
INCY icon
14
Incyte
INCY
$23.5B
$52.7M 3.58%
912,497
-469,214
-34% -$29.6M
XENE icon
15
Xenon Pharmaceuticals
XENE
$6.32B
$51M 3.46%
1,491,835
+502,508
+51% +$18.8M
AMAM
16
DELISTED
Ambrx Biopharma Inc
AMAM
$40.1M 2.72%
3,488,596
+1,838,097
+111% +$25M
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.84B
$34.7M 2.36%
2,390,077
-34,055
-1% -$644K
AUTL
18
Autolus Therapeutics
AUTL
$386M
$33.6M 2.28%
14,406,782
+5,189,632
+56% +$14.8M
TGTX icon
19
TG Therapeutics
TGTX
$8.58B
$30.3M 2.05%
+3,619,015
New +$50.5M
ZLAB icon
20
Zai Lab
ZLAB
$2.17B
$27.8M 1.88%
1,142,383
+277,086
+32% +$7.38M
ALPN
21
DELISTED
Alpine Immune Sciences Inc
ALPN
$27.7M 1.88%
2,421,743
-2,218
-0.1% -$27.3K
IMTX icon
22
Immatics
IMTX
$1.24B
$23.8M 1.62%
2,058,447
+73,634
+4% +$879K
VRNA
23
DELISTED
Verona Pharma
VRNA
$15.1M 1.02%
926,432
+32,571
+4% +$627K
CRBU icon
24
Caribou Biosciences
CRBU
$156M
$14.1M 0.96%
+2,944,513
New +$18.3M
VOR icon
25
Vor Biopharma
VOR
$1.04B
$13.7M 0.93%
323,073
– –
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Paradigm Biocapital Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Paradigm Biocapital Advisors held 38 positions worth $1.47B, up 14% from $1.29B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Paradigm Biocapital Advisors deployed $251M of net new capital in Q3 2023, opening 8 new positions and adding to 19 existing holdings. Its largest new stake was Disc Medicine: 1,272,279 shares worth $59.8M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 95% a quarter earlier.

On the sell side, the largest reduction was Incyte, an estimated $29.6M trimmed.

  • Paradigm Biocapital Advisors's largest Q3 2023 buy was Disc Medicine: 1,272,279 shares worth $59.8M.
  • Paradigm Biocapital Advisors added most to argenx in Q3 2023, an estimated $58.3M increase.
  • Paradigm Biocapital Advisors's biggest Q3 2023 reduction was Incyte, cutting an estimated $29.6M.
  • Paradigm Biocapital Advisors fully exited Karuna Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $61.5M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 61% of its $1.47B portfolio in Q3 2023.
  • Paradigm Biocapital Advisors opened 8 new positions and closed 7 in Q3 2023.
  • Paradigm Biocapital Advisors's portfolio value rose 14% quarter-over-quarter to $1.47B.

Based on Paradigm Biocapital Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.